Table 1.
Clinical characteristics of the synovial sarcoma cohort
| Case | Sitea | Sizeb (cm) | Therapy | Site of metastasis | Size of recurrencec (cm) | Subtype |
|---|---|---|---|---|---|---|
| 1 | right leg | 5.5 | SX + ChT | mpx lung, bone, CNS | no recurrence | monophasic |
| 2 | left ankle | 4 | SX + ChT | lung | no recurrence | biphasic |
| 3 | lung | NA | SX + ChT | lung | no recurrence | biphasic |
| 4 | gluteal region | 7 | SX + ChT | no metastasis | no recurrence | monophasic |
| 5 | left hand | 1 | SX + ChT | mpx lung | 2.8 | monophasic |
| 6 | left praesacral region | NA | SX + ChT | mpx lung | 4 | monophasic |
| 7 | left leg | NA | SX + ChT | mpx lung, liver | 3 | monophasic |
| 8 | abdominal wall | 10 | SX + ChT | no metastasis | 3.5 | monophasic |
| 9 | right palm | 3 | SX | no metastasis | 1.5 | biphasic |
| 10 | neck | NA | SX + RT + ChT | no metastasis | no recurrence | monophasic |
| 11 | left forearm | NA | SX + ChT | lung | 2.1 | monophasic |
| 12 | right forearm | 3.9 | SX + ChT | mpx lung, mediastinum | no recurrence | monophasic |
| 13 | right popliteal region | 10 | SX + ChT | mpx lung, kidney | NA | monophasic |
| 14 | right sole | 5 | SX + ChT | no metastasis | no recurrence | monophasic |
| 15 | left leg | NA | SX + ChT | mpx lung, pleura, mediastinum | no recurrence | biphasic |
alocation of the primary tumor; bmaximum diameter of the primary tumor; cmaximum diameter of the recurrent tumor; NA not available, SX surgical excision, ChT chemotherapy, RT radiotherapy, mpx multiplex, CNS central nervous system. Chemotherapy means the combination of the following agents: Epirubicin; VIP: 3 cycles of Etoposide, Ifosfamide and Cisplatin; Bisphosphonate; Dacarbazine; Vincristine; Pazopanib; Doxorubicin; Ifosfamide; Gemcytabine; Docetaxel; Carboplatin; Etoposide; CYVADIC: Cyclophosphamide, Vincristine, Adriamycin, Dacarbazine